Scarring/arrhythmogenic cardiomyopathy

Abstract The designation of ‘arrhythmogenic cardiomyopathy’ reflects the evolving concept of a heart muscle disease affecting not only the right ventricle (ARVC) but also the left ventricle (LV), with phenotypic variants characterized by a biventricular (BIV) or predominant LV involvement (ALVC). Herein, we use the term ‘scarring/arrhythmogenic cardiomyopathy (S/ACM)’ to emphasize that the disease phenotype is distinctively characterized by loss of ventricular myocardium due to myocyte death with subsequent fibrous or fibro-fatty scar tissue replacement. The myocardial scarring predisposes to potentially lethal ventricular arrhythmias and underlies the impairment of systolic ventricular function. S/ACM is an ‘umbrella term’ which includes a variety of conditions, either genetic or acquired (mostly post-inflammatory), sharing the typical ‘scarring’ phenotypic features of the disease. Differential diagnoses include ‘non-scarring’ heart diseases leading to either RV dilatation from left-to-right shunt or LV dilatation/dysfunction from a dilated cardiomyopathy. The development of 2020 upgraded criteria (‘Padua criteria’) for diagnosis of S/ACM reflected the evolving clinical experience with the expanding spectrum of S/ACM phenotypes and the advances in cardiac magnetic resonance (CMR) imaging. The Padua criteria aimed to improve the diagnosis of S/ACM by incorporation of CMR myocardial tissue characterization findings. Risk stratification of S/ACM patients is mostly based on arrhythmic burden and ventricular dysfunction severity, although other ECG or imaging parameters may have a role. Medical therapy is crucial for treatment of ventricular arrhythmias and heart failure. Implantable cardioverter defibrillator (ICD) is the only proven life-saving treatment, despite its significant morbidity because of device-related complications and inappropriate shocks. Selection of patients who can benefit the most from ICD therapy is one of the most challenging issues in clinical practice.

[1]  M. Link,et al.  Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice? , 2022, European heart journal.

[2]  D. Corrado,et al.  Evolving Diagnostic Criteria for Arrhythmogenic Cardiomyopathy , 2021, Journal of the American Heart Association.

[3]  D. Corrado,et al.  Arrhythmogenic left ventricular cardiomyopathy , 2021, Heart.

[4]  B. Giorgi,et al.  ‘Hot phase’ clinical presentation in arrhythmogenic cardiomyopathy , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  A. Mazzanti,et al.  Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. , 2020, International journal of cardiology.

[6]  D. Corrado,et al.  Arrhythmogenic Right Ventricular Cardiomyopathy: Characterization of Left Ventricular Phenotype and Differential Diagnosis With Dilated Cardiomyopathy , 2020, Journal of the American Heart Association.

[7]  M. Link,et al.  Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis , 2019, European heart journal.

[8]  A. Abidov,et al.  Arrhythmogenic cardiomyopathy , 2018, The EACVI Textbook of Cardiovascular Magnetic Resonance.

[9]  R. Weintraub,et al.  Dilated cardiomyopathy , 2017, The Lancet.

[10]  M. Link,et al.  Arrhythmogenic Right Ventricular Cardiomyopathy. , 2017, The New England journal of medicine.

[11]  S. Heymans,et al.  Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. , 2016, European heart journal.

[12]  D. Corrado,et al.  Arrhythmogenic Cardiomyopathy. , 2021, Circulation research.

[13]  M. Link,et al.  Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement , 2015, European heart journal.

[14]  D. Corrado,et al.  Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/dysplasia , 2010, Heart.

[15]  Wojciech Zareba,et al.  Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, Circulation.

[16]  A. Moorman,et al.  Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic right ventricular cardiomyopathy , 2009, The Journal of experimental medicine.

[17]  D. Corrado,et al.  Essay: Sudden death in young athletes , 2005, The Lancet.

[18]  M. Davies,et al.  Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. , 1997, Journal of the American College of Cardiology.

[19]  A. Angelini,et al.  Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? , 1996, Circulation.

[20]  D. Corrado,et al.  Right ventricular cardiomyopathy: is there evidence of an inflammatory aetiology? , 1991, European heart journal.